• 한국임상수의학회지
• /
• 제24권4호
• /
• pp.542-549
• /
• 2007

During a designated period(Jan. 2003$\sim$Jun. 2006), a total of 2,051 biopsy and necropsy cases submitted to Veterinary Medical Teaching Hospital of Seoul National University and local practitioners were diagnosed as canine tumors based on microscopic evaluation in the Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University. Four hundred and twenty of 2,051 tumor specimens excluding mammary(883, 43.1%) and cutaneous(748, 36.5%) tumors were included in this retrospective study. They were composed of genital tumors(189, 45.0%) followed by alimentary(113, 26.9%), hematopoietic(52, 12.4%), urinary(20, 4.8%), bone & joint(15, 3.6%), ocular & otic(9, 2.1%), respiratory(6, 1.4%), endocrine(6, 1.4%), and miscellaneous(10, 2.4%). Particular top ten tumor most frequently diagnosed were seminoma(48, 11.4%) followed by fibrous epulis(38, 9.0%), lymphoma(38, 9.0%), leiomyoma(33, 7.9%), fibroma(26, 6.2%), ovarian cyst(19, 4.5%), melanoma(15, 3.6%), papilloma(14, 3.3%), cystic endometrial hyperplasia(13, 3.1%), granulosa cell tumor(13, 3.1%) in descending order comprising 257(61.2%). The affected age of the animals with ten frequent tumors ranged from 3 months to 17 years old with a mean of 9.2 years old(n=218). There were no significant sex prevalence except female leiomyoma. The top seven anatomical sites of tumors inclusive were gingiva(62, 14.8%), testis(61, 14.5%), ovary(48, 11.4%), vagina(40, 9.5%), uterus(36, 8.6%), lymph node(30, 7.1%), and spleen(21, 5.0%).

• Journal of Veterinary Science
• /
• 제22권6호
• /
• pp.79.1-79.14
• /
• 2021

Background: In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool. Objectives: This study examined whether survivin could be suitable as a potential canine serum tumor marker. Methods: This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17). Results: Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively). Conclusions: The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.